These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30312670)

  • 21. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients.
    Baco E; Ukimura O; Rud E; Vlatkovic L; Svindland A; Aron M; Palmer S; Matsugasumi T; Marien A; Bernhard JC; Rewcastle JC; Eggesbø HB; Gill IS
    Eur Urol; 2015 Apr; 67(4):787-94. PubMed ID: 25240973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy.
    Berg KD; Røder MA; Brasso K; Vainer B; Iversen P
    Scand J Urol; 2014 Apr; 48(2):168-76. PubMed ID: 23889119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved accuracy in predicting the presence of Gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy.
    Numao N; Kawakami S; Yokoyama M; Yonese J; Arisawa C; Ishikawa Y; Ando M; Fukui I; Kihara K
    Eur Urol; 2007 Dec; 52(6):1663-8. PubMed ID: 17240041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study.
    Kvåle R; Møller B; Wahlqvist R; Fosså SD; Berner A; Busch C; Kyrdalen AE; Svindland A; Viset T; Halvorsen OJ
    BJU Int; 2009 Jun; 103(12):1647-54. PubMed ID: 19154461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Downgrading of biopsy based Gleason score in prostatectomy specimens.
    Treurniet KM; Trudel D; Sykes J; Evans AJ; Finelli A; Van der Kwast TH
    J Clin Pathol; 2014 Apr; 67(4):313-8. PubMed ID: 24403214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy.
    Pierorazio PM; Lin BM; Mullins JK; Hyndman ME; Schaeffer EM; Han M; Partin AW; Pavlovich CP
    Urol Oncol; 2013 Jul; 31(5):589-94. PubMed ID: 21664838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.
    Renard Penna R; Cancel-Tassin G; Comperat E; Mozer P; Léon P; Varinot J; Roupret M; Bitker MO; Lucidarme O; Cussenot O
    World J Urol; 2016 Oct; 34(10):1389-95. PubMed ID: 26902878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer.
    Graefen M; Ohori M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Erbersdobler A; Henke RP; Huland H; Wheeler TM; Slawin K; Scardino PT; Kattan MW
    J Urol; 2004 Jan; 171(1):200-3. PubMed ID: 14665876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy.
    Kozminski MA; Tomlins S; Cole A; Singhal U; Lu L; Skolarus TA; Palapattu GS; Montgomery JS; Weizer AZ; Mehra R; Hollenbeck BK; Miller DC; He C; Feng FY; Morgan TM
    Urol Oncol; 2016 Sep; 34(9):415.e1-6. PubMed ID: 27140065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis.
    Gorday W; Sadrzadeh H; de Koning L; Naugler CT
    Clin Biochem; 2015 Dec; 48(18):1230-4. PubMed ID: 26164541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series.
    Somford DM; Hambrock T; Hulsbergen-van de Kaa CA; Fütterer JJ; van Oort IM; van Basten JP; Karthaus HF; Witjes JA; Barentsz JO
    Invest Radiol; 2012 Mar; 47(3):153-8. PubMed ID: 22293513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy.
    Qi R; Foo WC; Ferrandino MN; Davis LG; Sekar S; Longo TA; Jibara G; Han T; Gokhan I; Moul JW
    Can J Urol; 2017 Oct; 24(5):8982-8989. PubMed ID: 28971784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
    Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
    BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.
    Loeb S; Folkvaljon Y; Robinson D; Lissbrant IF; Egevad L; Stattin P
    Eur Urol; 2016 Jun; 69(6):1135-41. PubMed ID: 26707871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid and Short-term Extracellular Matrix-mediated In Vitro Culturing of Tumor and Nontumor Human Primary Prostate Cells From Fresh Radical Prostatectomy Tissue.
    Chander AC; Manak MS; Varsanik JS; Hogan BJ; Mouraviev V; Zappala SM; Sant GR; Albala DM
    Urology; 2017 Jul; 105():91-100. PubMed ID: 28365358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate Biopsy Specimens With Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    Khani F; Epstein JI
    Am J Surg Pathol; 2015 Oct; 39(10):1383-9. PubMed ID: 26076065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.